Literature DB >> 15506157

Prices and availability of pharmaceuticals: evidence from nine countries.

Patricia M Danzon1, Michael F Furukawa.   

Abstract

This study compares average price levels for pharmaceuticals in eight countries--Canada, Chile, France, Germany, Italy, Japan, Mexico, and the United Kingdom--relative to the United States. Our most comprehensive indexes, adjusted for U.S. manufacturer discounts, show Japan's prices to be higher than U.S. prices, and other countries' prices ranging from 6 percent to 33 percent lower than U.S. prices. The decline of the Canadian dollar and rise of the U.K. pound contribute to the finding of lower Canadian prices and higher U.K. prices in 1999 than in 1992. Our findings suggest that U.S.-foreign price differentials are roughly in line with income and smaller for drugs than for other medical services.

Mesh:

Substances:

Year:  2003        PMID: 15506157     DOI: 10.1377/hlthaff.w3.521

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  20 in total

1.  The high cost of medicines in Ireland. Is it time to change the pricing mechanism?

Authors:  Lesley Tilson; Bernadette McGowan; Kathleen Bennett; Michael Barry
Journal:  Eur J Health Econ       Date:  2004-12

2.  Impact of parallel trade on pharmaceutical firm's profits: rise or fall?

Authors:  Shen Guo; Bin Hu; Hai Zhong
Journal:  Eur J Health Econ       Date:  2013-04

3.  Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

Authors:  Carl Rudolf Blankart; Tom Stargardt; Jonas Schreyögg
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

4.  Price differentiation and transparency in the global pharmaceutical marketplace.

Authors:  David B Ridley
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).

Authors:  Avi Dor; Mark V Pauly; Margaret A Eichleay; Philip J Held
Journal:  Int J Health Care Finance Econ       Date:  2007-09

6.  Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.

Authors:  Margaret K Kyle; Jennifer S Allsbrook; Kevin A Schulman
Journal:  Health Serv Res       Date:  2008-03-12       Impact factor: 3.402

7.  Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs.

Authors:  Kurt Richard Brekke; Dag Morten Dalen; Tor Helge Holmås
Journal:  Eur J Health Econ       Date:  2013-10-22

8.  Why U.S. health care expenditure and ranking on health care indicators are so different from Canada's.

Authors:  A H G M Spithoven
Journal:  Int J Health Care Finance Econ       Date:  2008-07-01

9.  Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.

Authors:  Patricia M Danzon
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

10.  Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.

Authors:  Steven Sheingold; Nguyen Xuan Nguyen
Journal:  Medicare Medicaid Res Rev       Date:  2014-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.